Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 (trastuzumab emtansine) which is sold under the brand name Kadcycla. Treatment of early ...
If breast cancer has higher than normal levels of HER2 it is classified as HER2 positive. People with this type of breast cancer normally receive chemotherapy as well as targeted treatments, called ...
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
The European Union’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion to Roche’s Perjeta (pertuzumab) for use in combination with herceptin (trastuzumab) and ...
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with ...